MiNK Therapeutics, Inc. — Q3 2022 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2022. MiNK is a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (iNKT) cell therapies. The company reported no revenue in the presented statements.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Research and development expense | $6.15 million | $3.33 million | $17.30 million | $10.02 million |
| General and administrative expense | $1.84 million | $0.81 million | $5.76 million | $2.28 million |
| Net loss | $6.33 million | $14.27 million | $20.22 million | $24.45 million |
| Net loss per share, basic and diluted | $0.19 | $0.59 | $0.60 | $1.01 |
| Cash used in operating activities | Not separately stated | Not separately stated | $14.44 million | $11.12 million |
At September 30, 2022, cash and cash equivalents were $24.16 million, down from $38.89 million at December 31, 2021. Current assets were $24.46 million and current liabilities were $18.45 million. Total assets were $25.26 million, and stockholders’ equity was $6.76 million. Accumulated deficit was $103.17 million. No gross margin or profit margin is presented; the company is pre-revenue and loss-making.
Current liabilities included $8.36 million due to related parties. The prior Agenus convertible note had converted into shares in October 2021 and was not outstanding at quarter-end. Cash equivalents included $20.02 million in institutional money market funds.
Changes versus comparable periods
- Q3 R&D expense increased 84% year over year; management attributed the increase to clinical-trial advancement, preclinical work, and personnel costs related to internalizing manufacturing.
- Q3 G&A expense increased 126%, primarily from higher personnel and stock-based compensation, professional fees, and insurance costs.
- Despite higher operating expenses, quarterly net loss was lower than in Q3 2021, when results included a $9.23 million charge from the fair-value change in the Agenus convertible note. The note was converted in October 2021.
- For the nine-month period, net loss narrowed year over year, while operating cash use increased. The 2022 period included a $2.7 million gain related to a reduction in the recorded Walloon Region advance liability.
Outlook, commentary, and risks
- Management expects operating losses and negative cash flows to continue, but stated that quarter-end cash should cover liquidity needs for more than one year from the financial-statement issuance date. The company may adjust spending and identifies partnering, out-licensing, debt, or equity financing as potential funding sources.
- AGENT-797 is the most advanced candidate. The company reported Phase 1 trials in multiple myeloma and solid tumors, described preliminary activity signals in multiple myeloma, and planned to present trial updates at the Q4 2022 SITC conference. These were forward-looking statements, not reported outcomes in this filing.
- MiNK said it had completed internal cGMP production of AGENT-797 and reported expansion capacity intended to treat more than 700,000 patients per year. BCMA-CAR-iNKT and FAP-CAR-iNKT remained in preclinical development, with IND-enabling studies initiated in 2022.
- AGENT-797 for infections and viral ARDS was identified as selectable for DARPA funding; contract negotiations were underway. Funding was not stated as secured.
- The Walloon Region obtained a default judgment seeking approximately $2.0 million repayment. MiNK recorded a remaining $2.0 million liability and said it was evaluating options to challenge or resolve the judgment. The filing’s legal-proceedings section separately states MiNK was not party to material legal proceedings.
- The company cited clinical, regulatory, manufacturing, financing, competition, intellectual-property, third-party-dependence, and related-party risks. It is majority-owned by Agenus and receives services from Agenus under intercompany arrangements.
Key facts for investors to verify
- Whether cash burn and development spending remain consistent with management’s stated runway of more than one year, and whether additional financing becomes necessary.
- Clinical-trial enrollment, safety, efficacy, and timing of AGENT-797 data; the filing’s anticipated SITC updates were forward-looking.
- The status and potential resolution or payment of the Walloon Region judgment and the remaining $2.0 million liability.
- Whether DARPA contract negotiations result in funding, and whether reported manufacturing capacity translates into reliable production.
- The costs and terms of Agenus-related services, the $8.36 million due to related parties, and the implications of Agenus’s majority ownership.